- Home
- PRMB vs QGEN Comparison
PRMB vs QGEN Comparison
Compare PRMB & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRMB | QGEN |
|---|---|---|
| Founded | 1955 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | 2025 | 1998 |
Fundamental Metrics
Financial Performance| Metric | PRMB | QGEN |
|---|---|---|
| Price | $19.25 | $45.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $30.27 | ★ $47.73 |
| AVG Volume (30 Days) | ★ 4.2M | 2.0M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | 2.48% | ★ 6.20% |
| EPS Growth | ★ 328.57 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $6,664,000,000.00 | N/A |
| Revenue This Year | $2.60 | $2.18 |
| Revenue Next Year | $3.49 | $5.06 |
| P/E Ratio | $74.38 | ★ $24.01 |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $14.36 | $32.53 |
| 52 Week High | $26.21 | $57.82 |
Technical Indicators
Market Signals| Indicator | PRMB | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 57.10 |
| Support Level | $19.17 | $45.39 |
| Resistance Level | $19.72 | $49.43 |
| Average True Range (ATR) | 0.64 | 1.14 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 22.95 | 67.60 |
Price Performance
Historical ComparisonAbout PRMB Primo Brands Corporation
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).